Results of Annual General Mee

RNS Number : 5926U

Hikma Pharmaceuticals Plc

15 May 2008

 



Hikma Pharmaceuticals PLC - Results of Annual General Meeting

LONDON, 15 May 2008 - Hikma Pharmaceuticals PLC ('the Company') advises that at its Annual General Meeting of shareholders, held at the Andaz Hotel, 40 Liverpool Street, London, that began at 11.00am today, 15 May 2008, resolutions 1 to 7 contained in the Notice of Annual General Meeting were passed as ordinary resolutions on a show of hands. Resolutions 8 and 9 were passed as special resolutions on a show of hands 

Copies of the resolutions dealing with special business passed at the Annual General Meeting have been submitted to the UK Listing Authority for publication through the Listing Authority's Document and Viewing Facility.  

The total number of proxies received for each resolution is set out below. The total number of votes received for each resolution is set out below. The number of Ordinary Shares in issue on 15 May 2008 was 188,588,607.

	Resolution	Votes        For	%	Votes Against	%	Discretion	%	Votes Withheld
1	To receive the 2007 report and accounts	80,463,625	63.89	267,877	0.21	46,350,091	35.90	86,857
2	To declare a final dividend	80,735,343	64.06	83,016	0.07	46,350,091	35.87	-
3	Reappointment of Mr Said Darwazah	78,552,076	63.43	85,403	0.07	46,350,091	36.50	2,180,880
4	Reappointment of Deloitte and Touche as auditors	80,576,256	64.02	82,324	0.06	46,350,091	35.92	159,779
5	Authorise the directors to set the remuneration of the auditors	80,732,985	64.06	85,324	0.07	46,350,091	35.87	50
6	To receive and approve the Remuneration Report	80,544,132	64.05	8,079	0.01	46,350,091	35.94	266,148
7	Authorise the directors to allot shares	77,910,142	61.82	2,908,217	2.31	46,350,091	35.87	-
8	Disapply pre-emption rights	78,062,847	61.94	2,230,120	1.77	46,875,483	36.29	-
9	Amend the Articles of Association	77,716,543	61.80	2,311,526	1.84	46,875,483	36.36	264,898

Notes:

• The discretionary votes granted to the Chairman were voted in favour of the resolutions. 

• A 'vote withheld' is not a vote in law and is not counted in the calculation of the proportion of the votes 'for' and 'against' a resolution.    

Declaration of final dividend

The final dividend of 4.0 cents per share will be paid on 2 June 2008 to shareholders on the register on 2 May 2008. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend is 1.9480 US dollars to one Pound Sterling, equal to approximately 2.05 pence per share. Shareholders resident in Jordan have been given the opportunity to receive the dividend in Jordanian Dinar, at a rate of 0.708 Jordanian Dinar per US dollar.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Henry Knowles Company Secretary	[phone]
Susan Ringdal Investor Relations Director	[phone]

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products.  Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'.  Hikma's operations are based principally in the Middle East and North Africa ('MENA') region, where it is a market leader and sells across 17 countries, the United States and Europe.  In 2007, the Group achieved revenues of $449 million (2006 $317 million) and profit attributable to shareholders was $63 million (2006 $55 million).  For news and other information, please visit www.hikma.com.

 

END

 

 

RAGSFIFMISASESI